Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 9,512 matching trials from the live ClinicalTrials.gov search.
Filters: Birmingham, Alabama Clear all
Completed Phase 1 Interventional

A Comparison of Saquinavir Hard- and Soft-Gelatin Capsules in HIV-Infected Patients

NCT00002383
View directory record Official record
Conditions
HIV Infections
Interventions
Saquinavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Sherman Oaks, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 1:39 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of 4975 in Patients Undergoing Total Knee Replacement

NCT00681356
View directory record Official record
Conditions
Total Knee Arthroplasty (Replacement)
Interventions
4975, 15 and 5 mg, Placebo Comparator, 4975 - 5 mg
Drug
Lead sponsor
Anesiva, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
25
States / cities
Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 20 more
Source: ClinicalTrials.gov public record
Updated May 4, 2009 · Synced Oct 17, 2026, 1:39 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine

NCT02974153
View directory record Official record
Conditions
Migraine Disorders
Interventions
ALD403 (Eptinezumab), Placebo
Biological
Lead sponsor
Alder Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
74
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 65 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 17, 2026, 1:39 PM EDT
Completed Phase 2 Interventional Results available

Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis

NCT06144424
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Oral EP262, Placebo
Drug
Lead sponsor
Escient Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Birmingham, Alabama • Miami Lakes, Florida • Plainfield, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 17, 2026, 1:39 PM EDT
Completed Phase 3 Interventional

Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

NCT04677569
View directory record Official record
Conditions
Mycobacterium Infections, Nontuberculous
Interventions
ALIS, Azithromycin, Ethambutol, ELC (matching placebo for ALIS)
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
90
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 71 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 17, 2026, 1:39 PM EDT
Completed Phase 3 Interventional Results available

SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

NCT01718483
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
43
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Corona, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 17, 2026, 1:39 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF

NCT02846324
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Hypoxemia
Interventions
GBT440, Placebo
Drug
Lead sponsor
Global Blood Therapeutics
Industry
Eligibility
45 Years to 80 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
12
States / cities
Birmingham, Alabama • San Francisco, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 17, 2026, 1:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Patient Activation After DXA Result Notification

NCT01507662
View directory record Official record
Conditions
Osteoporosis, Bone Diseases, Metabolic
Interventions
Bone Mineral Density Result Letter and Bone Health Brochure
Behavioral
Lead sponsor
Fredric D Wolinsky
Other
Eligibility
50 Years and older
Enrollment
7,749 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
3
States / cities
Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 17, 2026, 1:39 PM EDT
Completed Not applicable Interventional Results available

A Study to Compare the NexGen LPS and LPS-Flex Knee Implants

NCT00763386
View directory record Official record
Conditions
Total Knee Arthroplasty, Osteoarthritis
Interventions
NexGen LPS-Flex Fixed Bearing Knee, NexGen Legacy Posterior Stabilized Knee
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
21 Years to 80 Years
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
14
States / cities
Birmingham, Alabama • Decatur, Georgia • Springfield, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 17, 2026, 1:39 PM EDT
Not yet recruiting Not applicable Interventional

The Effect of Lateral Extra-Articular Tenodesis on Lower-Extremity Lean Mass Recovery Following Anterior Cruciate Ligament Reconstruction

NCT07777458
View directory record Official record
Conditions
Anterior Cruciate Ligament Reconstruction (ACLR)
Interventions
Bone-patellar Tendon-bone (BTB), Bone-patellar Tendon-bone (BTB) and Lateral Extra-Articular Tenodesis (LET)
Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
16 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 1:39 PM EDT
Completed Not applicable Interventional Results available

Optimizing Protein Patterns for Skeletal Muscle Preservation and Sleep in the Medical Management of Parkinson Disease

NCT05437640
View directory record Official record
Conditions
Parkinson Disease
Interventions
Protein Redistribution Diet, Protein Consistent Diet
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
45 Years to 99 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 17, 2026, 1:39 PM EDT
Withdrawn Not applicable Interventional

Immune Effects of Low-dose Naltrexone in ME/CFS

NCT02965768
View directory record Official record
Conditions
Fatigue Syndrome, Chronic
Interventions
Naltrexone HCl
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 2, 2022 · Synced Oct 17, 2026, 1:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

CONDOR Study of Osteonecrosis of the Jaws (TMJ)

NCT01130389
View directory record Official record
Conditions
Osteonecrosis of the Jaw
Interventions
Not listed
Lead sponsor
Dental Practice-Based Research Network
Network
Eligibility
40 Years and older
Enrollment
309 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
5
States / cities
Birmingham, Alabama • Minneapolis, Minnesota • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Oct 17, 2026, 1:39 PM EDT
Completed Phase 2 Interventional

Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease

NCT00811889
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes, Diabetic Nephropathy
Interventions
Placebo, Bardoxolone Methyl (RTA 402)
Other · Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
42
States / cities
Birmingham, Alabama • Montgomery, Alabama • Chula Vista, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 17, 2026, 1:39 PM EDT
Recruiting Phase 3 Interventional

Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))

NCT05135091
View directory record Official record
Conditions
Mesial Temporal Lobe Epilepsy
Interventions
NRTX-1001, Sham Comparator
Biological · Procedure
Lead sponsor
Neurona Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2043
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 17, 2026, 1:39 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease

NCT04120493
View directory record Official record
Conditions
Huntington's Disease
Interventions
intra-striatal rAAV5-miHTT, Imitation (sham) surgery
Genetic · Other
Lead sponsor
UniQure Biopharma B.V.
Industry
Eligibility
25 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
12
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 17, 2026, 1:39 PM EDT
Completed Phase 2 Interventional Results available

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

NCT01461538
View directory record Official record
Conditions
Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Anemia, Refractory, With Excess of Blasts, Solid Tumors
Interventions
brentuximab vedotin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
6 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
29
States / cities
Birmingham, Alabama • Duarte, California • Oxnard, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2016 · Synced Oct 17, 2026, 1:39 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma

NCT02336425
View directory record Official record
Conditions
Asthma
Interventions
QGE031, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Birmingham, Alabama • Kingwood, Texas • Plano, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2017 · Synced Oct 17, 2026, 1:39 PM EDT
Withdrawn No phase listed Observational

Mitochondrial Dysfunction Contributes to Sepsis Induced Cardiac Dysfunction

NCT05148117
View directory record Official record
Conditions
Sepsis
Interventions
Suspected Sepsis Group - Diagnostic Measurements, Control Group - Diagnostic Measurements
Diagnostic Test
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 17, 2026, 1:39 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older

NCT07734649
View directory record Official record
Conditions
Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization, Healthy Volunteers
Interventions
RSV+HMPV vaccine, Control Vaccine 3, Control Vaccine 4, Control Vaccine 2, Placebo, Control Vaccine 1
Biological · Other
Lead sponsor
Sanofi
Industry
Eligibility
60 Years and older
Enrollment
2,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
50
States / cities
Gadsden, Alabama • Vestavia Hills, Alabama • Huntington Beach, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 17, 2026, 1:39 PM EDT
Terminated Phase 1 Interventional

Pilot Study of Pentoxifylline for Hepatopulmonary Syndrome

NCT00593658
View directory record Official record
Conditions
Hepatopulmonary Syndrome
Interventions
pentoxifylline
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Oct 17, 2026, 1:39 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Adapting Enhanced Recovery Programs for Low Health Literacy Patients

NCT06356558
View directory record Official record
Conditions
Surgery, Health Knowledge, Attitudes, Practice, Colorectal Disorders
Interventions
Educational intervention (VISACT)
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
1,050 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 17, 2026, 1:39 PM EDT
Completed Phase 2 Interventional Results available

Neo-Penotran Forte Vaginal Suppository for Vaginal Trichomoniasis

NCT01361048
View directory record Official record
Conditions
Trichomonas Vaginitis
Interventions
oral metronidazole, neo penotran forte, neo penotran forte once a day
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 19, 2018 · Synced Oct 17, 2026, 1:39 PM EDT
Completed Phase 3 Interventional

Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease

NCT04750226
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
ABBV-951
Drug
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
47
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 17, 2026, 1:39 PM EDT